Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05985954
Phase
PHASE1
Status
Recruiting

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cetuximab — DRUG
    Given by IV (vein)
  • Ulixertinib — DRUG
    Given by PO
  • Encorafenib — DRUG
    Given by PO

Study Details

To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.

Key Dates

Start date
Jan 18, 2024
Status verified
Mar 2026
Primary completion
Mar 28, 2028
Completion
Mar 28, 2028

Study Design

Enrollment
27 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BRAF Expansion Cohort
    1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab and encorafenib.
  • Experimental: Cohort A
    1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab alone.

Primary Outcome Measure

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Christine Parseghian, MD
713-792-2828
Christine Parseghian, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Related Studies